The Effect of Budesonide Inhaler on chronic lung disease prevention in neonates with RDS and gestational age of lower than 28 weeks
Phase 2
- Conditions
- Chronic Lung Disease.Bronchitis, not specified as acute or chronic
- Registration Number
- IRCT2015112810430N6
- Lead Sponsor
- Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
* 23 to 28 weeks gestational age.
* compatible clinical symptoms of RDS (Respiratory Disease Syndrome) as (tachypnea, intercostal retraction, nasal flaring, grunting, and the need for supplemental oxygen).
* letter of consent.
Exclusion criteria:
* congenital malformation.
* prinatal asphyxia.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Chronic lung disease prevention. Timepoint: 4 weeks after birth. Method of measurement: The need for supplementary oxygen.
- Secondary Outcome Measures
Name Time Method Reduction in need for surfactant. Timepoint: 72 hours after birth. Method of measurement: The need for supplementary oxygen more than 40%.